Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosis
- 1 January 2007
- journal article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 97 (06) , 907-913
- https://doi.org/10.1160/th06-12-0745
Abstract
The effect of the 675 insertion/deletion (4G/5G) polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene on the risk of venous thromboembolism (VTE) remains controversial. In this study, we performed a meta-analysis of published data regarding this issue. A comprehensive electronic search was carried out up until September 2006. A total of 22 articles were included in the analysis that was performed using random effects models. Eighteen papers, concerning patients without another known risk factor, comprised 2,644 cases and 3,739 controls. The alleles contrast (4G vs. 5G allele) yielded a statistically significant odds ratio (OR) of 1.153 (95% confidence interval [CI]: 1.068–1.246). In a sub-analysis of five studies that included 256 cases with another genetic risk factor and 147 controls, the combined per-allele OR was still significant (OR:1.833,95% CI:1.325–2.536). On the contrary, the analysis of five studies regarding cases with a non-genetic risk factor for VTE (antiphospholipid antibody syndrome, Behcet disease) provided insignificant results in all aspects. There was no evidence for heterogeneity and publication bias in all analyses. Based on our findings, the 4G allele appears to increase the risk of venous thrombosis, particularly in subjects with other genetic thrombophilic defects. Recommendation for detection of this polymorphism in evaluating thrombophilia in such patients might be considered.Keywords
This publication has 10 references indexed in Scilit:
- Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controlsThe Lancet, 2006
- Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levelsThrombosis and Haemostasis, 2004
- Plasminogen activator inhibitor-type 1: its plasma determinants and relation with cardiovascular riskThrombosis and Haemostasis, 2004
- Factor V Leiden, prothrombin 20210G → A, methylenetetrahydrofolate reductase 677C → T and plasminogen activator inhibitor 4G/5G polymorphism in women with pregnancy-related venous thromboembolismEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2003
- Measuring inconsistency in meta-analysesBMJ, 2003
- Prospective study of fibrinolytic markers and venous thromboembolismJournal of Clinical Epidemiology, 2003
- Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's diseaseBlood Coagulation & Fibrinolysis, 2003
- Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosisThrombosis and Haemostasis, 2003
- PAI‐1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organsAmerican Journal of Hematology, 2002
- The Role of the t-PA I/D and PAI-1 4G/5G Polymorphisms in African-American Adults With a Diagnosis of Myocardial Infarction or Venous ThromboembolismThrombosis Research, 2000